STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (NASDAQ:STDAF) has earned an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.

Zacks has also assigned STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) an industry rank of 110 out of 265 based on the ratings given to its competitors.

Separately, DZ Bank AG restated a “sell” rating on shares of STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) in a report on Monday, July 10th.

STADA ARZNEIMITTEL NP (NASDAQ STDAF) traded up 3.76% during mid-day trading on Friday, hitting $96.60. The stock had a trading volume of 100 shares. The company has a 50 day moving average price of $83.27 and a 200-day moving average price of $71.66. STADA ARZNEIMITTEL NP has a one year low of $45.80 and a one year high of $97.45. The company has a market cap of $6.01 billion and a price-to-earnings ratio of 54.51.

ILLEGAL ACTIVITY NOTICE: “Zacks: STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (STDAF) Given Consensus Recommendation of “Hold” by Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/09/zacks-stada-arzneimittel-npvregd-vinkuliert-stdaf-given-consensus-recommendation-of-hold-by-analysts.html.

Get a free copy of the Zacks research report on STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (STDAF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) and related companies with MarketBeat.com's FREE daily email newsletter.